Market analysts issue new ratings for various technology and biotech firms

Various companies across the technology and biopharmaceutical sectors have recently received updated evaluations from market analysts.

In the biopharmaceutical space, BTIG Research reaffirmed ‘buy’ ratings for Consensus Cloud Solutions, Cullinan Therapeutics, and Nektar Therapeutics. Nektar Therapeutics received a high price target of $178.00, while Cullinan Therapeutics was given a $40.00 target. TG Therapeutics currently holds a consensus ‘Hold’ rating among nine analysts, despite some individual ‘buy’ and ‘sell’ recommendations.

In the technology sector, Trimble received a rating upgrade from ‘Hold’ to ‘Buy’ from Wall Street Zen. Trimble reported second-quarter revenue of $972 million, exceeding expectations, and maintains a consensus price target of approximately $81.78.